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of the acid a-glucosidase (GAA) enzyme and results in progres-
sive wasting of skeletal muscle cells. The c.-32-13T>G (IVS1)
GAA variant promotes exon 2 skipping during pre-mRNA
splicing and is the most common variant for the childhood/
adult disease form. We previously identiﬁed antisense oligonu-
cleotides (AONs) that promoted GAA exon 2 inclusion in
patient-derived ﬁbroblasts. It was unknown how these AONs
would affect GAA splicing in skeletal muscle cells. To test
this, we expanded induced pluripotent stem cell (iPSC)-derived
myogenic progenitors and differentiated these to multinucle-
ated myotubes. AONs restored splicing in myotubes to a
similar extent as in ﬁbroblasts, suggesting that they act by
modulating the action of shared splicing regulators. AONs tar-
geted the putative polypyrimidine tract of a cryptic splice
acceptor site that was part of a pseudo exon in GAA intron 1.
Blocking of the cryptic splice donor of the pseudo exon with
AONs likewise promoted GAA exon 2 inclusion. The simulta-
neous blocking of the cryptic acceptor and cryptic donor sites
restored the majority of canonical splicing and alleviated
GAA enzyme deﬁciency. These results highlight the relevance
of cryptic splicing in human disease and its potential as thera-
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Cell type-speciﬁc alternative pre-mRNA splicing is evolutionary
conserved and plays a critical role in cell type-speciﬁc functions.1,2
The involved mechanisms include the differential expression of
splicing regulatory proteins, guided by cell type-speciﬁc master
splicing factors.3 In human disease, aberrant pre-mRNA splicing
plays a causal role in at least 9% of known cases (http://www.hgmd.
cf.ac.uk/), and this likely represents an underestimation.4 Aberrant
splicing is amenable to modulation with drugs that either target
splicing regulatory proteins or that block cis-acting splicing regu-
latory elements such as canonical or cryptic splice sites or exonic or
intronic splicing silencer/enhancer sequences. To test these drugs
for possible further clinical development, in vitro and in vivo modelsMolecul
This is an open access article under the CC BY-Nare required that closely mimic splicing events that occur in the rele-
vant cell type of human patients. In particular when targeting cis-
acting splicing regulatory elements with sequence-speciﬁc antisense
oligonucleotides (AONs), the availability of human cells is important
as evolutionary conservation at the RNA level is generally poor.
We recently identiﬁed AONs that correct aberrant splicing in ﬁbro-
blasts from patients with childhood/adult onset Pompe disease caused
by the common variant c.-32-13T>G (IVS1) in the gene encoding the
lysosomal enzyme acid alpha glucosidase (GAA).5 Pompe disease is a
monogenic autosomal recessive disorder characterized by progressive
muscle wasting. Classic infantile patients are affected at birth by
hypertrophic cardiomyopathy and skeletal muscle wasting.6 These
patients carry GAA mutations that result in a residual GAA enzyme
activity of <1% of the average activity in healthy controls. Patients
with childhood/adult Pompe disease have a later disease onset
ranging from 3 to 60 years of age and have progressive skeletal
muscle wasting, but no cardiac phenotype.7 Residual GAA enzyme
activity in these patients is between 1% and 20% of average healthy
control values. Enzyme replacement therapy (ERT) for Pompe dis-
ease is available in which recombinant human GAA is administered
(bi)weekly intravenously.6,8,9 Although ERT is effective, not all pa-
tients respond well, its long-term efﬁcacy is insufﬁcient, and it isar Therapy: Nucleic Acids Vol. 7 June 2017 ª 2017 The Author(s). 101
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Nucleic Acidsvery expensive.10–12 For these reasons, an alternative treatment op-
tion is required.
The IVS1 GAA variant occurs in 90% of adults and 50% of children in
the Netherlands with Pompe disease and in similarly high percentages
of Caucasian Pompe patients in other countries.13,14 Therefore, it
forms an attractive target for a potential novel therapy. The IVS1
variant is located in the polypyrimidine tract (pY-tract) of GAA
exon 2 and weakens the recognition of the splice acceptor site of
this exon.13,15,16 AONs that restored splicing were identiﬁed in a
screen for cis-acting splicing silencer elements, and these targeted
an element in intron 1, 175 nucleotides upstream of the affected
exon 2.5 It was unclear from this study whether the AON-mediated
inhibition of a putative splicing silencer element would be operational
in differentiated skeletal muscle cells, which represent the cell type
relevant for Pompe disease, and what the underlying mechanism
was. To this end, we developed an in vitro model using patient-
derived skeletal muscle cells. We generated induced pluripotent
stem cells (iPSCs) from patients with childhood/adult Pompe disease
caused by the IVS1 GAA variant. iPSCs were differentiated into
myogenic progenitors using a modiﬁed transgene-free protocol,17
and myogenic progenitors were expanded and differentiated into
multinucleated myotubes to test the efﬁcacy and mechanism of
AONs that correct the IVS1 GAA variant. This showed that the
IVS1 variant promoted utilization of a pseudo exon, and that the
simultaneous blocking of the 30 and 50 cryptic splice sites of this
pseudo exon with AONs resulted in restoration of the majority of ca-
nonical splicing and GAA enzyme activity. The results highlight the
feasibility to correct the IVS1 variant in skeletal muscle cells from
Pompe patients using AONs, and they underscore the potential of
modulating cryptic splicing to correct human disease.
RESULTS
Generation and Characterization of iPSCs from Pompe Patients
Carrying the IVS1 GAA Variant
To generate iPSCs from patients with childhood/adult Pompe dis-
ease caused by the IVS1 GAA variant, primary ﬁbroblasts were re-
programmed using a polycistronic lentiviral vector of Oct4, Sox2,
Klf4, and c-Myc.18 Two patients were modeled. Patient 1 carried
the IVS1 variant on one allele and the c.525delT variant on the
other allele. The c.525delT variant causes a reading frameshift,
and the mRNA expressed from this allele is degraded, facilitating
detection of splicing forms from the IVS1 allele.19 Patient 2 carried
the IVS1 variant on one allele and the c.923A > C missense variant
on the second allele.20 This missense variant allows mRNA expres-
sion without degradation to at least 50% of normal levels. Fibro-
blasts from a healthy control were also reprogrammed; a second,
independent healthy control has been described previously.21 The
three lines generated here were characterized using standard
procedures. Immunoﬂuorescent analysis indicated that all three
lines expressed pluripotency markers including NANOG, OCT4,
SSEA4, TRA-1-80 and TRA-1-61 (Figure S1A). In vitro differentia-
tion showed that all three lines were capable of differentiating into
cell-types of the three germ layers monitored by expression of a-fe-102 Molecular Therapy: Nucleic Acids Vol. 7 June 2017toprotein (AFP), smooth muscle actin (SMA), and class III
b-tubulin (TUJI) (Figure S1B). Microarray analysis showed expres-
sion of essential pluripotent genes comparable to human embryonic
stem cell (hESC) lines H1 and H9 and reduction of ﬁbroblast-asso-
ciated genes (Figure S1C). All iPSC lines contained normal karyo-
types (Figure S1D).
Differentiation of iPSCs intoMyotubes via ExpandableMyogenic
Progenitors
To differentiate iPSCs into skeletal muscle cells, we used a recently
published transgene-free protocol.17 This protocol consists of activa-
tion of WNT signaling using GSK3b inhibition, followed by an
expansion phase mediated by FGF2 (Figure 1AI). Initial experiments
resulted in Pax7+ cells after a 35-day period (Figure 1B), suggesting
that muscle progenitors had formed. These cells were present in
patches among other cell types. All experiments yielded Pax7+ cells,
but percentages of obtained Pax7+ cells depended on concentration
and duration of GSK3b inhibitor CHIR99021. Treatment with a
higher concentration of CHIR99021 (3.5 mM) for a longer duration
(5–6 days) was well tolerated without signs of toxicity and resulted
in the generation of higher yields of Pax7+ cells. The generation of
Pax7+ cells using this protocol was highly reproducible and was
observed in all >30 independent differentiation experiments,
although yields still varied between experiments (data not shown).
Pax7+ cells were puriﬁed by ﬂuorescence-activated cell sorting
(FACS) using C-Met+/Hnk1 cells. These could be further differenti-
ated into multinucleated myotubes within 5–9 days (Figure S2A).
Typical yields of puriﬁed cells were between 50,000 and 250,000
myogenic progenitors derived from 1 106 iPSCs after a 35-day pro-
tocol. Cells puriﬁed at lower yields showed decreased capacity to form
multinucleated myotubes (data not shown).
To improve the yields of myogenic progenitors and the robustness of
myogenic differentiation, expansion of muscle cells after FACS was
tested. FGF2 was included in the expansion medium because it
is known to induce proliferation and to inhibit differentiation of
myogenic cells.22 We tried ﬁve conditions (Table S1) and only basic
DMEM supplemented with 10% FBS and 100 ng/mL FGF2 was sup-
portive of myogenic progenitor proliferation and resulted in an
expansion of at least 5  107-fold in 15 passages (Figures 1AII and
1C). Upon expansion, the karyotype remained normal (Figure 1D).
MyoD was expressed in virtually all cells during the expansion period
(Figure 1E). Cryopreservation of the expanded culture was possible
at any moment and yielded high viabilities upon thawing. Expanded
cells showed efﬁcient and homogeneous differentiation into multinu-
cleated myotubes with similair fusion index that expressed myosin
heavy chain (MHC) (Figures 2A, S2B, and S2C). Proliferating
myogenic progenitors were characterized by high expression of the
myogenic markers MyoD, Myogenin, Six1, and Six4, moderately
high expression of the myogenic differentiation marker a-actinin
and of FGF2, while the neural crest marker Sox1 was not expressed
(Figure 2B). In addition, at any stage of expansion, cells could be
differentiated into multinucleated myotubes with a high fusion index
(tested in >500 differentiations performed to date) (Figures S2B and
Figure 1. Expansion of Purified iPSC-Derived Myogenic Progenitors
(A) I, Scheme for differentiation of iPSCs intomyogenic progenitors and FACS purification; II, Expansion of purifiedmyogenic progenitors. The expansion medium is indicated.
The fold expansion is indicated. (B) Immunofluorescent staining for Pax7 (in red) in selected areas from a culture dish derived from non-purified myogenic progenitors
following the 35-day differentiation protocol. The nuclei were stained with Hoechst (blue). (C) Linear proliferation curves for all four iPSC-derived myogenic progenitor lines
during expansion. The average R2 shownwas calculated for all data points of the four lines and indicates high concordance between the four lines. (D) Karyotype analysis after
expansion of purified myogenic progenitors at day 35 (a representative example of ten nuclei). (E) Immunofluorescent analysis of MyoD in FACS purified and expanded
myogenic progenitors. Myogenic progenitors were expanded in proliferation medium and stained at the start of expansion and after expansion to 1012 cells. Representative
pictures are shown in the image.
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Figure 2. Differentiation of iPSC-Derived Myogenic Progenitors into Multinucleated Myotubes
(A) Myogenic progenitors retain their capacity to differentiate into multinucleated myotubes during expansion. Myogenic progenitors were expanded, and at several time points
during expansion a subculturewas differentiated for 4 days and stained for expression of themyogenic differentiationmarkerMHC (MF-20 antibody; red). The nuclei were stained
withHoechst (blue). Thewhite arrowheadspoint to examples of alignednuclei present in a singlemyotube. The fusion index of eachdifferentiation is shown at the bottom. Thedata
are means ± SDs of five technical replicates. (B) mRNA expression of iPSC-derived myogenic progenitors (purified and expanded) andmyotubes thereof. Equal amounts of total
RNAwere isolated fromfibroblasts (F),myogenic progenitors (MP), andmyotubes (MT), generated after 4 days of differentiation, andmRNAexpression of the indicated geneswas
determined by qRT-PCR analysis. Log fold change was calculated relative to control 1 sample 1. The lines represent means. Biological duplicates are shown in the image.
Molecular Therapy: Nucleic AcidsS2C). Multinucleated myotubes showed high expression of the
myogenic differentiation marker a-actinin, while b-actin expression
was reduced relative to myogenic progenitors (Figure 2B). We
conclude that expansion of myogenic progenitors provided sufﬁcient
amounts of cells to allow the testing of AONs on their potential to
correct aberrant splicing from the IVS1 allele in myotubes.104 Molecular Therapy: Nucleic Acids Vol. 7 June 2017Splicing Modulation in iPSC-Derived Myotubes
Since splicing regulation can be cell type-speciﬁc,2 it was a priori
possible that the IVS1 variant caused qualitative or quantitative
splicing differences in skeletal muscle cells compared to ﬁbroblasts.
It was also not clear to what extent the results on splicing modula-
tion by AONs in ﬁbroblasts could be extended to skeletal muscle
Figure 3. GAA Splicing and Enzyme Activity in Fibroblasts and Myotubes
from Pompe Patients
(A) Equal amounts of total RNA from primary fibroblasts (F) and their corresponding
iPSC-derived myotubes (MT), derived from patient 1 or a healthy control, were
analyzed by flanking exons 1–3 RT-PCR ofGAA exon 2. N: WT product, SV2: splice
variant 2, SV3: splice variant 3. (B) As (A), but now as analyzed by qRT-PCR of
individual splicing products. To facilitate comparison between different cell types, no
normalization was used and all products were compared to the value of average
control fibroblast product N levels using the delta-Ct method. (C) GAA enzyme
activity in iPSC-derived multinucleated myotubes. Myogenic progenitors from the
cells indicated were differentiated for 4 days, and the GAA enzyme activity was
determined. The average activity present in the two healthy controls paralleled those
present in fibroblasts (data not shown) and was used to calculate the percentage of
residual activity in myotubes from the two patients.
www.moleculartherapy.orgcells. To test this, patient-derived iPSCs were differentiated into my-
otubes, and the effect of the IVS1 variant on splicing was compared
to the effect observed in ﬁbroblasts. Figure 3A shows the results of
the ﬂanking exon RT-PCR analysis. The effect of the IVS1 variant
was similar in ﬁbroblasts compared to skeletal muscle myotubes.
Products from myotubes at the position of the splicing products
N, SV2, and SV3 were sequenced and found to be identical to their
counterparts in ﬁbroblasts (data not shown). Control myotubes did
not show obvious aberrant GAA pre-mRNA splicing, similar to ﬁ-
broblasts. Quantitative analysis of individual splicing products using
qRT-PCR showed that the wild-type splicing product N was ex-
pressed to slightly higher levels in control myotubes, but to slightly
lower levels in Pompe myotubes compared to ﬁbroblasts (Figure 3B).
The SV3 product was slightly higher in Pompe myotubes comparedto Pompe ﬁbroblasts. Myotubes from both Pompe patients showed
partial residual GAA enzyme activity consistent with residual leaky
wild-type splicing (Figure 3C). This indicates that the IVS1 variant
causes similar aberrant splicing in ﬁbroblasts and skeletal muscle
cells.
Next, we tested the effect of AONs 3 and 4, which we identiﬁed
recently to promote exon inclusion in ﬁbroblasts5 on exon 2 inclusion
in myotubes. Figure 4A shows the effect of AON 3 on GAA exon 2
splicing in myotubes from patient 1, as analyzed by RT-PCR using
primers annealing to exon 1 and 3. AON 3 caused a concentration-
dependent increase in exon 2 inclusion, as judged from the increase
in the amounts of the wild-type variant (N) and a concomitant
decrease in the amounts of the partial (SV3) and full exon 2 skip
(SV2) variants. This was conﬁrmed by quantitative analysis using
qRT-PCR with primers speciﬁc for individual splicing variants in my-
otubes from patient 1 treated with AON 3 (Figure 4B) and AON 4
(Figure 4C) and in myotubes from patient 2 treated wth AON 3 (Fig-
ure S3A) and AON 4 (Figure S3B). No effect of AONs 3 and 4 onGAA
expression and exon 2 splicing was observed in myotubes from con-
trol iPSCs (Figures 4D and S3C). These results indicate that AONs 3
and 4 corrected aberrant exon 2 splicing caused by the IVS1 variant in
patient-derived myotubes by promoting exon 2 inclusion during
splicing. AON 3 and 4 enhanced GAA enzymatic activity inmyotubes
derived from patient 1 (Figure 4E) and patient 2 (Figure S3D) up to
2-fold and was ineffective in myotubes from control 1 (Figure 4F)
and control 2 (Figure S3E). These efﬁcacies were similar to those
observed in ﬁbroblasts.5 AON treatment was well tolerated. Stainings
with anti-MHC and anti-myogenin antibodies showed no effects of
AON treatment of the transfection itself, AON 3 or 4 (Figures 4G,
S3G, and S3H) on differentiation. In addition, qRT-PCR analysis
showed no consistent changes in expression of MyoD, Myogenin,
LAMP1, or LAMP2 (Figure S3F). Taken together, the AONs 3
and 4 corrected aberrant GAA exon 2 splicing in patient-derived
myotubes, and they elevated GAA enzyme activity with similar efﬁ-
cacy as in ﬁbroblasts.
Identification of a Pseudo Exon that Competes with Exon 2
Splicing
As it was unclear how AONs 3 and 4 restored exon 2 inclusion, we
were interested to investigate their mechanism of action. We noted
that the target sequence of these AONs showed similarity to a
pY-tract, which is usually present between 5–40 nt upstream of a
splice acceptor. We then performed in silico analysis of splice sites us-
ing Alamut, and this predicted a strong natural cryptic splice acceptor
site 12–13 nt downstream of the binding site for AONs 3 and 4 (Fig-
ure 5A). At 102 nt further downstream, a strong natural cryptic splice
donor was predicted. These predictions were found for the wild-type
GAA gene and were unchanged by the IVS1 variant, suggesting that
these cryptic splice sites deﬁned a hypothetical natural pseudo
exon. Usage of the natural pseudo exon was observed in a minigene
construct harboring the IVS1 variant. Mutation of the natural cryptic
splice sites of the natural pseudo exon abolished its inclusion in
the context of the minigene harboring the IVS1 variant (FiguresMolecular Therapy: Nucleic Acids Vol. 7 June 2017 105
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www.moleculartherapy.orgS4A–S4C). This suggested the possibility that AONs 3 and 4 may act
by inhibiting usage of a natural pseudo exon rather than by repressing
a putative intronic splice silencer.
To test this, we ﬁrst analyzed whether splice products comprising
the putative natural pseudo exon exist in cells from Pompe patients.
To this end, mRNA isolated from patient-derived myotubes was
analyzed by ﬂanking exon RT-PCR of exon 2, and PCR products
were cloned into a TOPO vector. There were 96 clones that were
analyzed by Sanger sequencing, and this resulted in the identiﬁcation
of eight splice variants (Figures 5B and 5C; Table 1 [column: colony
count mock transfection] and S4D). The predicted natural pseudo
exon was indeed detected in two splice products in which exon 2
was fully (SV6) or partially (SV5) skipped, but at a low abundance.
It is likely that both products are subject to mRNA degradation due
to the lack of the translation start codon. Nevertheless, these could
also be identiﬁed on agarose gels following ﬂanking exon PCR of
exon 2 (Figure 5B). Other low abundant splice products (SV1, SV4,
and SV7) utilized a previously described cryptic splice donor nearby
exon 1.15,16 However, these never contained the natural pseudo exon.
These data suggest that the predicted natural pseudo exon exists
in vivo in splice products in which exon 2 is partially or fully skipped
due to the IVS1 variant.
Short introns are unfavorable for successful splicing and have a
typical minimum length of 70–80 nt.23 The length of the intron be-
tween the natural pseudo exon and exon 2 is 52 nt, which violates
this rule. This suggested the possibility that inclusion of the natural
pseudo exon competes with exon 2 inclusion, which would be in
agreement with themutually exclusive inclusion of the natural pseudo
exon or exon 2 in splice products. Such scenario would explain why
AONs 3 and 4 promote exon 2 inclusion, namely by repression of in-
clusion of the natural pseudo exon via interfering with the pY-tract of
the natural cryptic splice acceptor site. We hypothesized that repres-
sion of the natural cryptic splice donor would likewise promote exon
2 inclusion. To test this, AON 5 was designed to target the natural
cryptic splice donor site of the natural pseudo exon (Figure 5A). In
patient-derived myotubes, AON 5 promoted exon 2 inclusion (prod-
uct N) and repressed inclusion of the natural pseudo exon (products
SV5 and SV6), as shown by ﬂanking exon RT-PCR and splicing prod-
uct-speciﬁc qRT-PCR (Figures 5B, 5D, and S4E). AON 5 was equally
effective in splicing correction compared to AON 3, suggesting that
both AONs prevent utilization of the natural pseudo exon. GAA
enzyme activity was enhanced by AON 5 to similar levels comparedFigure 4. Quantitative Analysis of GAA Exon 2 Splicing in Expanded iPSC-Deri
(A) Flanking exon RT-PCR analysis of the effect of AON 3 on GAA exon 2 splicing in my
myotubes from patient 1 as analyzed with qRT-PCR analysis of individual splicing prod
consistent changes in expression:MyoD,Myogenin, LAMP1, and LAMP2 (see Figure S3
myotubes from control 1 as analyzed with qRT-PCR analysis of splice product N. The c
normalization was as in (B). (E) Effects of AON 3 and 4 onGAA enzymatic activity in myotu
does not affect myogenic differentiation. Immunofluorescent stainings of myotubes after
blue: nuclei (Hoechst). 0 mM: mock transfection. Representative pictures are shown in t
0.05, **p < 0.01, and ***p < 0.001.to AON 3 (Figure 5E) and myotube differentiation was not altered by
AON treatment (Figure 5F). These results are in agreement with the
idea that the natural pseudo exon competes with exon 2 splicing and
that natural pseudo exon skipping by AONs promotes exon 2
inclusion.
To test whether the simultaneous targeting of the cryptic splice
acceptor and donor sites of the pseudo exon would further promote
exon inclusion, a combination of AON 3 plus AON 5 was tested in
patient-derived myotubes. At the same total AON concentrations,
combinations of AON 3 plus AON 5 were equally effective as single
AON treatments in promoting exon 2 inclusion and repressing aber-
rant exon 2 splicing (Figures 5B and 5D). We used TOPO cloning as
above to analyze all products that arise from treatment with AON 3
plus AON 5 (Table 1). No additional products besides the eight
known splicing products were identiﬁed. Compared to mock treated
cells, cells treated with AON 3 plus 5 showed an increase in the
number of clones with a wild-type exon 2 insert from 14 to 45
(3.2- fold), while the number of clones that contained the natural
pseudo exon was reduced 6-fold from 6 to 1 (Table 1). When tested
on GAA enzyme activity, combinations of AONs 3 plus 5 were
slightly more efﬁcient compared to single AONs and caused
enhancement of up to 4-fold (Figure 5E). In addition, 76 kDa active
GAA protein levels were quantiﬁed and demonstrated similar levels
of active GAA protein as shown by the GAA enzyme activity assay
(Figure S5B and S5C). It is unclear why the mRNA data do not fully
match the GAA enzyme activity data. We note that the error bars are
smaller in the GAA enzyme assay, as this assay is very sensitive and
accurate, suggesting a technical reason. The restoration of canonical
splicing was efﬁcient, but incomplete, as small amounts of aberrant
splice products were still detected. This was in particular the case for
SV2 and SV3. This suggests that prevention of inclusion of the
pseudo exon was not sufﬁcient to fully restore aberrant splicing.
The maximal possible enhancement of GAA enzyme activity using
this approach is 3.5–5-fold: patients with the IVS1 allele have on
average 10%–15% leaky wild-type splicing and full restoration will
amount to a maximum of 50% (derived from one allele) of the
average value of healthy controls. AONs 3 plus 5 promoted GAA
exon 2 inclusion and GAA activity in myotubes with 3.3-fold,
indicating that these corrected 66%–99% of exon 2 splicing. We
conclude that the simultaneous inhibition of the cryptic splice donor
and acceptor sites of the natural pseudo exon restore the majority of
GAA splicing and GAA enzymatic activity in patient-derived skeletal
muscle cells.ved Myotubes
otubes from patient 1 and control 1. (B) Effect of AON 3 on GAA exon 2 splicing in
ucts. The data were normalized against expression of four genes that showed no
F). (C) As (B), but now for AON 4. (D) Effect of AONs 3 and 4 onGAA exon 2 splicing in
ontrol cells have undetectable levels of aberrant splice products SV2 and SV3. The
bes from patient 1. (F) As (E), but now inmyotubes from control 1. (G) AON treatment
treatment with AONs 3 and 4 are shown. Red: MHC (anti-MF-20); green: Myogenin;
he image. The quantitative data are means ± SDs of three biological replicates. *p <
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Table 1. Analysis of Splice Variants by TOPO Cloning
Splice Variant
Colony Count Mock
Transfection
Colony Count Transfection
of 15 mM AON 3 and 5
Total 96 96
Readable 93 90
N 14 45
SV1 3 3
SV2 44 16
SV3 24 23
SV4 0 2
SV5 4 1
SV6 2 0
SV7 2 0
www.moleculartherapy.orgDISCUSSION
We evaluated the effect of the common IVS1 GAA variant on
splicing in skeletal muscle cells, the relevant cell type for child-
hood/adult Pompe disease, in vitro. In addition, we tested whether
previously identiﬁed AONs that promoted exon 2 inclusion in ﬁbro-
blasts carrying the IVS1 variant were also capable of doing so in skel-
etal muscle cells. By reprogramming patient-derived ﬁbroblasts to
iPSCs, we generated myogenic progenitors using a transgene-free
protocol and expanded puriﬁed myogenic cells to allow quantitative
analysis in multinucleated myotubes. This showed that the IVS1
variant caused exon skipping, and that AONs promoted exon inclu-
sion and enhanced GAA enzymatic activity in myotubes similar as in
ﬁbroblasts. We found that the AONs targeted the pY-tract of a
cryptic splice acceptor site that was part of a pseudo exon. The simul-
taneous blocking of 50 and 30 splice sites of the pseudo exon resulted
in promotion of exon inclusion and rescue of the majority of GAA
enzyme activity. The results suggest that the splicing machinery uti-
lizes alternative splice sites when the canonical splice acceptor site is
weakened by the IVS1 variant, and that blocking of such cryptic
splice sites using AONs is capable to restore canonical exon
inclusion.
Several in vitro models for Pompe disease have been published. Most
of these concern the classic infantile form, and in these reports iPSCs
were differentiated into cardiomyocytes that showed hallmarks ofFigure 5. Blocking of a Natural Pseudo Exon Restores GAA Exon 2 Splicing
(A) The splicing silencer in intron 1 is predicted to be the pY-tract of a natural pseudo e
previously.5 Note that predictions were independent of the IVS1 variant. A strong 30 sp
suggested the presence of a natural pseudo exon, indicated by “p” in the cartoon. Th
indicated. (B) Blocking of natural pseudo exon splicing restores GAA exon 2 splicing. AON
alone or in combination in myotubes from patient 1. Flanking RT-PCR analysis ofGAA ex
cloning (see Table 1) of products obtained from the flanking exon RT-PCR in (B). (D) Ana
the natural pseudo exon is represented by SV5 and SV6, and these products were quant
genes that showed no consistent changes in expression: MyoD, Myogenin, LAMP1, a
activity. (F) Combined treatment with AONs 3 and 5 does not interfere with myogenic diff
of iPSC-derived myotubes obtained from patient 1. Red, MHC (anti-MF-20); green, myo
shown in the image. The quantitative data are means ± SDs of three biological replicatPompe disease including GAA deﬁciency, glycogen accumulation,
and newly identiﬁed glycan processing abnormalities.24–27
Classic infantile patients are characterized by left ventricle hypertro-
phic cardiomyopathy, severe skeletal muscle wasting resulting in
hypotonia and respiratory failure, and CNS abnormalities. In child-
hood and adult forms of Pompe disease, skeletal muscle wasting is
prominent, but cardiac abnormalities are more rare, and there is
no evidence for CNS abnormalities.28–30 A recent report described
the generation of myocytes, using MyoD overexpression, from iPSCs
derived from adult Pompe patients who did not carry the IVS1
variant.26 These cells showed increased levels of total glycogen.
To our knowledge, our report presents the ﬁrst iPSC models
for childhood/adult Pompe disease that carry the IVS1 variant.
Following a 4-day differentiation protocol into myotubes, we did
not observe major differences in size and number of lysosomes using
LAMP1 immunoﬂuorescent analysis (data not shown), despite the
GAA enzyme deﬁciency in these cells. We anticipate that the devel-
opment of lysosomal abnormalities in childhood/adult cells in vitro
may take time, as it does in patients. Disease onset is heterogeneous
and may occur between the age of 3 and 60 years. This may be ex-
plained by modifying factors that affect Pompe disease onset and
progression.14,31 We are currently optimizing culture conditions to
allow long-term analysis of differentiated myogenic cells to test
this. We note that lysosomal pathology and glycogen accumulation
in vitro in ﬁbroblasts are only detectable by immunoﬂuorescent
LAMP1 staining or by biochemical analysis of glycogen content,
respectively, following a period of 3 weeks of conﬂuent, non-prolif-
erating culture and only in cells from classic infantile patients, but
never in cells from childhood/adult patients.32 This suggests that
lysosomal glycogen only accumulates under certain conditions and
can be prevented by active cell proliferation. In childhood/adult
Pompe patients, lysosomal pathology in skeletal muscle biopsies is
very heterogeneous. Typically, virtually normal myoﬁbers lay adja-
cent to strongly affected ﬁbers.6 It is poorly understood why certain
ﬁbers escape pathology, while others do not. Future research is
required to identify critical determinants of lysosomal glycogen
accumulation.
Transgene-free differentiation of human iPSCs into myogenic cells
has been achieved by a number of laboratories.17,33–38 The basic pro-
tocol consists of activation of the WNT signaling pathway, followedxon. Alamut was used to predict splice sites around the splicing silencer identified
lice site was predicted at c.-32-154, and a strong 50 splice site at c.-32-53, which
e canonical 30 splice site of exon 2 at c.-32 showed strong prediction and is also
5 was designed to block the predicted 50 splice site, and AONs 3 and 5 were tested
on 2 was performed. (C) Cartoons of splicing products that were identified by TOPO
lysis of the experiment in (B) by qRT-PCR of individual splicing products. Splicing to
ified using unique PCR primers. The data were normalized against expression of four
nd LAMP2 (see Figure S4E). (E) Analysis of the experiment in (B) on GAA enzyme
erentiation to myotubes. Immunofluorescent staining results are shown for treatment
genin; blue, nuclei (Hoechst); 0 mM, mock transfection. Representative pictures are
es. *p < 0.05, **p < 0.01, and ***p < 0.001.
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Figure 6. Model for Promotion of Exon Inclusion in
Cells with the IVS1 GAA Variant
Top: natural cryptic splice sites define a pseudo exon that
is silent in healthy individuals. Middle: a pathogenic variant
weakens a canonical splice acceptor site, resulting in
inclusion of the pseudo exon and skipping of the ca-
nonical exon. Bottom: simultaneous blocking of the nat-
ural cryptic splice acceptor and splice donor sites of the
pseudo exon prevents inclusion of the pseudo exon and
promotes inclusion of the canonical exon. Splice site
strength is indicated by the length of the blue (donor sites)
and green (acceptor sites) bars. The natural pseudo exon
is indicated in red. AONs are indicated as combs. The
boxes represent exons, and the dashed lines introns.
Molecular Therapy: Nucleic Acidsby an expansion period using FGF2. BMP inhibition has been used to
prevent formation of neural crest.34 Alternatively, neural crest and
other non-myogenic cells have been removed by FACS, similar as
performed here.17,33 In our hands, recoveries and differentiation ca-
pacities were heterogeneous directly following FACS. We showed
that it is feasible to expand the puriﬁed cells using medium containing
FGF2. This resulted in a stable condition that allowed for rapid expan-
sion in proliferation medium and viable freezing or differentiation at
any desired time point up to the point of 5  107-fold expansion.
These conditions allowed the reproducible testing of drugs such as
AONs. This may present a general strategy for drug testing in
iPSC-derived models of other neuromuscular disorders. Other labo-
ratories also have shown expansion of myogenic progenitors.33,35,36,39
Hosoyama and colleagues35 demonstrated expansion in a sphere
based culture. Shelton et al.39 used a pre-plating protocol to expand
myogenic progenitors in the original plate used to induce myogenic
differentiation. Choi and coworkers33 reported expansion of puriﬁed
iPSC-derived myogenic progenitors of at least 1  104-fold. These
cells were generated using a modiﬁed protocol that used DAPT
instead of FGF2 followed by FACS with NCAM+/HNK markers
for puriﬁcation. Caron et al.36 pre-plated cells 10 days after starting
the differentiation protocol. It will be interesting to compare the
different protocols for generating and expanding myogenic progeni-
tors in more detail to test whether they yield myogenic progenitors
with similar or different properties. This should elucidate whether
myogenic cells generated in vitro relate to different types of myogenic
progenitors that have been identiﬁed in vivo, such as fetal or adult
muscle stem cells from different anatomical locations and in different
states of activation.
Master splicing factors have been identiﬁed that regulate tissue-spe-
ciﬁc splicing. In skeletal muscle, these include Rbfox1, RBM38, and
MBNL3.3 This highlights the need to evaluate splicing in the cell
type of interest, in particular, when testing potential drugs that modu-110 Molecular Therapy: Nucleic Acids Vol. 7 June 2017late splicing such as AONs. In this case, GAA
splicing abnormalities caused by the IVS1
variant and the effects of AONs on GAA
splicing appeared similar in ﬁbroblasts and
myotubes. This suggests that splicing of exon2 is not subject to regulation by the aforementioned master splicing
factors and may be regulated by more general splicing factors that
are also expressed in ﬁbroblasts. We hypothesize that the IVS1 variant
weakens the canonical splice acceptor of exon 2 such that the general
splicing machinery prefers to utilize the nearby cryptic splice site of
the pseudo exon (Figure 6). In healthy cells, this cryptic splice site
is overruled by the strength of the canonical splice acceptor. Blocking
of the cryptic splice acceptor, but also of the cryptic splice donor of the
pseudo exon, prevents the splicing machinery from utilizing these
sites, and when this occurs efﬁciently, the best available option is
the weakened, but functional canonical splice acceptor of exon 2.
While we originally anticipated that exon 2 splicing may be regulated
by classical splice silencer motifs, we were surprised to ﬁnd that this it
is in fact regulated by cryptic splicing. In this respect, the IVS1 variant
resembles other cases of cryptic splicing in Pompe disease that we
analyzed previously and that could be restored using AONs.40 This
ﬁnding highlights that the possibility of a shift toward cryptic splicing
in human disease should be considered when designing AON-based
therapies (Figure 6).
Further work is required to translate these ﬁndings to a clinical
setting. A combination of two AONs that have a larger effect
than individual AONs at the same total AON dose may offer the pos-
sibility to lower the dose, which should be conﬁrmed in animal
and clinical studies. Encouraging progress toward clinical implemen-
tation has been reported for other neuromuscular disorders including
SMA41,42 and DMD43,44 (reviewed by Havens et al.45). We anticipate
that it will be important to promote cellular uptake of AONs in skel-
etal muscle cells applied via the circulation. Ongoing efforts focus on
various strategies including cell penetrating peptides, exosomes,
nanoparticles, and stimulation of ATP-dependent transport using
hexose.46–50 Implementation of enhancers of cellular uptake may
form the next generation of AONs that will be tested in vivo as poten-
tial targeted therapies of human disease.
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Generation of iPSCs
Primary ﬁbroblasts from control 1, patient 1 (c.-32-13T>G/
c.525delT), and patient 2 (c.-32-13T>G/c.923A>C) (see van der
Wal et al.5) were reprogrammed into iPSCs using a polycistronic len-
tiviral vector of Oct4, Sox2, Klf4, and c-Myc as described.18 The Eras-
mus Medical Center (MC) institutional review board approved the
study protocol. iPSC line for control 2 was a gift from Christian
Freund and Christine Mummery and has been characterized previ-
ously.21 iPSCs were cultured on g-irradiated mouse embryonic feeder
(MEF) cells. The iPSC culture medium consisted of DMEM/F12 me-
dium (Invitrogen), 20% knockout serum replacement (Invitrogen),
1% non-essential amino acids (Gibco), 1% penicillin/streptomycin/
L-glutamine (100, Gibco), 2 mM b-mercaptoethanol (Invitrogen),
and 20 ng/mL basic ﬁbroblast growth factor (PeproTech). Human
ES lines H1 and H9 were obtained from WiCell Research Institute,
Madison, WI, USA. The identity of cell lines used in this study was
conﬁrmed by DNA sequence and microarray analyses. All cell lines
were routinely tested for mycoplasma infection using the MycoAlert
Mycoplasma Detection Kit (Lonza) and were found negative.Immunofluorescence
Cells were cultured on normal tissue culture dishes and ﬁxed with 4%
paraformaldehyde (Merck) in PBS for 10 min at room temperature,
washed with PBS, and permeabilized for 5 min with 0.1% Triton
X-100 (AppliChem) in PBS. Blocking was performed for 30 min at
room temperature with blocking solution containing PBS-T (0.1%
Tween, Sigma-Aldrich) with 3% BSA (Sigma-Aldrich). Primary anti-
bodies (Table S2) were diluted into 0.1% BSA in PBS-T and incubated
1 hr at room temperature. After incubation cells were washed three
times for 5 min with PBS-T and incubated with the secondary anti-
bodies (1:500, Alexa Fluor-594-a-goat, Alexa Fluor-488-a-mouse,
Alexa Fluor-594-a-rabbit, Alexa Fluor-488-a-rabbit, Invitrogen or
horse anti-mouse biotin, Vector Laboratories) in PBS-T for 30 min
at room temperature. For incubations with secondary biotinylated
antibodies, cells were washed three times for 5 min with PBS-T and
incubated with Streptavidine 594 (1:500, Invitrogen). The cells were
subsequently washed two times for 5 min with PBS and incubated
for 15 min with Hoechst (1:15,000, Thermo Scientiﬁc). Cells were
imaged in PBS.Microarray Analysis
RNA samples to be analyzed by microarrays were prepared using
RNeasy columns with on-column DNA digestion (QIAGEN). There
were 300 ng of total RNA per sample that were used as input into a
linear ampliﬁcation protocol (Ambion), which involved synthesis of
T7-linked double-stranded cDNA and 12 hr of in vitro transcription
incorporating biotin-labeled nucleotides. Puriﬁed and labeled cRNA
was then hybridized for 18 hr onto HumanHT-12 v4 expression
BeadChips (Illumina) following the manufacturer’s instructions. Af-
ter recommended washing, chips were stained with streptavidin-Cy3
(GE Healthcare) and scanned using the iScan reader (Illumina) and
accompanying software. Samples were exclusively hybridized as bio-logical replicates. The bead intensities were mapped to gene informa-
tion using BeadStudio 3.2 (Illumina). Background correction was
performed using the affymetrix robust multi-array analysis (RMA)
background correction model.51 Variance stabilization was per-
formed using the log2 scaling and gene expression normalization
was calculated with the method implemented in the lumi package
of R-Bioconductor. Data post-processing and graphics were per-
formed with in-house developed functions in MATLAB. Hierarchical
clustering of genes and samples was performed with one minus cor-
relation metric and the unweighted average distance (UPGMA) (also
known as group average) linkage method. The microarray data have
been made available online at Gene Expression Omnibus: GSE75713.
Differentiation of iPSCs to Derivatives of the Three Germ Layers
iPSC colonies were washed once with PBS and treated for 45min with
1 mg/mL collagenases IV (Invitrogen) at 37C, scraped, and centri-
fuged for 15 s at 800 rpm. The pellet was slowly resuspended in EB
medium (iPSC culture medium without FGF2) containing 10 mM
Y-27632 dihydrochloride (Ascent Scientiﬁc) and plated on low bind-
ing plates (Cytoone). For endodermal differentiation, 10 mM SB
431542 (Ascent Scientiﬁc) was added to the EB medium. 6 days later,
EBs were plated in 12 wells coated with 0.1% gelatin (Sigma-Aldrich)
for endodermal and mesodermal differentiation or with matrigel-
coated plates for ectodermal differentiation in endoderm/meso-
derm/ectoderm medium (Table S3). Cells were ﬁxed after 14 days
of differentiation with 4% paraformaldehyde (Merck) in PBS for
5 min at room temperature and processed for immunoﬂuorescence.
Karyotype Analysis
iPSCs or myogenic progenitors were detached with TrypLe (Gibco)
for 5 min at 37C. The pellet was incubated with 10 mg/mL colcemid
(Gibco) for 30 min at room temperature. Cells were then centrifuged
for 10 min at 1,100 rpm, resuspended in pre-warmed 0.075 M KCl,
and incubated for 10 min at 37C. After incubation cells were washed
ﬁve times with ﬁxation solution (3:1 methanol:acetic acid) and spread
onto glass slides. Hoechst staining was performed as described above.
There were 15 slides that were analyzed per cell line.
Differentiation of iPSCs to Myogenic Progenitors
Differentiation of iPSCs to myogenic progenitors cells was modiﬁed
from Borchin et al.17 Brieﬂy, 0.6 mm large iPSC colonies cultured
in 10 cm dishes on MEF feeders were treated for 5 days with
3.5 mM CHIR99021 (Axon Medchem) in myogenic differentiation
medium (DMEM/F12, 1 ITS-X and 1 Penicillin/Streptomycin/
Glutamine, all Gibco). CHIR99021 was removed and cells were
cultured in myogenic differentiation medium containing 20 ng/mL
FGF2 (Prepotech) for 14 days and were then cultured for an addi-
tional 16 days in myogenic differentiation medium only. Medium
was refreshed daily.
Purification of Myogenic Progenitors Using FACS
Following the 35-day protocol for differentiating iPSCs into a mixture
of cells including myogenic progenitors as outlined above, cells were
harvested and puriﬁed by FACS. To this end, cells were washed onceMolecular Therapy: Nucleic Acids Vol. 7 June 2017 111
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gently detached with a pipetboy. The cell suspension was ﬁltered
through a 40 mM FACS strainer (Falcon) to remove cell aggregates.
Cells were centrifuged for 4 min at 1,000 rpm and incubated with
anti-HNK-1-FITC (1:100, Aviva Systems Biology) and anti-C-
MET-APC (1:50, R&D Systems) antibodies for 30 min on ice in
myogenic differentiation medium. Cells were washed three times
with ice-cold 1% BSA in PBS before FACS sorting. Hoechst (33258,
Life Technologies) was used as viability marker. Hoechst/C-MET-
positive cells were sorted with a 100 mm nozzle and collected in
ice-cold iPSC-myogenic progenitor proliferation medium (iPSC-
MPC-pro medium) containing DMEM high glucose (Gibco) supple-
mented with 100 U/mL Penicillin/Streptomycin/Glutamine (Life
Technologies), 10% fetal bovine serum (Hyclone, Thermo Scientiﬁc),
and 100 ng/mL FGF2 (PeproTech). To reduce cell death, mediumwas
supplemented with 1 RevitaCell Supplement (Gibco) during collec-
tion and the ﬁrst 24 hr of cell culture. Sorting time was limited to
20 min per well. Plates/well were coated for 30 min at room temper-
ature with ECM (E6909-5 mL, 1:200 in iPSC-MPC-pro medium,
Sigma Aldrich). Sorted cells were plated either at 40,000 cells in one
well of a 48-well plate or at 80,000 cells in one well of a 24-well plate,
depending on the amount of cells.
Expansion of Myogenic Progenitors
At 1 day after plating FACS sorted myogenic progenitors, the
medium was refreshed with iPSC-MPC-pro medium. When cells
reached 90% conﬂuence, cells were passaged using 2 diluted TrypLe
in PBS and plated on ECM-coated plastic. Myogenic progenitors
could be frozen at any time during expansion without loss of prolif-
eration and differentiation capacity, using iPSC-MPC-pro medium
supplemented with 10% DMSO.
Differentiation of Myogenic Progenitors into Multinucleated
Myotubes
For differentiation to multinucleated myotubes, myogenic progeni-
tors were grown to 90% conﬂuence, and the medium was then
replaced with myogenic differentiation medium (DMEM/F12, 1
ITS-X and penicillin/streptomycin/glutamine, all Gibco). After
4 days, myotubes were harvested.
Production of LV-OSKM Lentivirus
The LV-OSKM lentivirus was produced in HEK293T cells cultured
in DMEM high glucose (Gibco) with 10% fetal bovine serum
(Thermo Scientiﬁc) supplemented with 100 U/mL Penicillin/Strepto-
mycin/Glutamine (Gibco). There were 80% conﬂuent HEK293T cells
that were transfected in 10 cm culture dishes with 3 mg LV-OSKM
reprogramming vector,18 2 mg psPAX2, and 1 mg pVSV packaging
vectors per dish using Fugene 6 transfection reagent according to
the manufacturer’s protocol (Promega). For concentration, 72 hr af-
ter transfection, medium was ﬁltered with 0.45 mm PVDF ﬁlters
(Millipore) and centrifuged for 2 hr at 20,000 rpm with a Beckman
Coulter Ultracentrifuge with SW 32 Ti Rotor. The pellet was dis-
solved in 25 mL DMEM low glucose (Gibco) per 10 cm dish and
stored at 80C.112 Molecular Therapy: Nucleic Acids Vol. 7 June 2017AON Transfections
At day 1 or day 0 prior to differentiation, myogenic progenitors
were transfected with Morpholino AONs (Table S4) using 4.5 mL en-
doporter reagent (Gene Tools) per milliliter of medium. After 4 days
of differentiation myotubes were harvested. In our previous study, a
control AON targeting CypA showed no effect on GAA mRNA
expression and no toxic effects were observed.5 We tested in addition
the effect of control AON1 (which targets GAA c.-32-219_-200) and
the standard control from Gene Tools (which targets HBB c.316-
162_138) in iPSC-derived skeletal muscle and found no effects on
GAA protein expression and no toxicity (Figure S5).
RNA Isolation and cDNA Synthesis
RNeasy Mini Kit with DNase treatment (QIAGEN) was used to
extract RNA. RNA was eluted in RNase-free water and stored
at 80C. There were 500 ng of RNA that were reverse transcribed
into cDNA using the iScript cDNA Synthesis Kit (Bio-Rad).
qRT-PCR
The qRT-PCR reaction consisted of a 15 mLmix with 7.5 mL iTaq Uni-
versal SYBR Green Supermix (Bio-Rad), 10 pmol/mL forward and
reverse primers (Table S5), and cDNA (5, 10, or 20 diluted)
measured with a CFX96 real-time system (Bio-Rad). For each plate,
a standard curve was included with 4–6 dilutions. Quantiﬁcation of
expression was calculated relative to expression of four markers
(Myog,MyoD, LAMP1, and LAMP2) in experiments where myotubes
were used and to RNA input in experiments were multiple tissues
(ﬁbroblasts, myogenic progenitors, and myotubes) were compared.
Flanking Exon RT-PCR
RT-PCR was performed with the Advantage GC 2 PCR Kit (Clon-
tech) with a GC-melt concentration of 0.5 M according to manufac-
tory instructions with primers from Table S4 and ten times diluted
cDNA. The RT-PCR reaction was analyzed on a 1.5% agarose gel con-
taining 0.5 mg/mL ethidium bromide (Sigma-Aldrich).
GAA Enzyme Activity Assay
Cells were lysed for 10 min on ice with ice cold lysis buffer containing:
50 mM Tris (pH 7.5), 100 mM NaCl, 50 mM NaF, 1% Triton X-100,
and one tablet Protease Inhibitor Cocktail cOmplete, with EDTA,
(Roche). The substrate 4-methylumbelliferyl a-D-glucopyranoside
(4-MU; Sigma-Aldrich) was used to measure GAA enzyme activity
as described previously.52 A BCA protein assay kit (Pierce, Thermo
Scientiﬁc) was used to determine total protein concentration.
GAA Protein Detection
iPSC-derivedmyogenic progenitors from control 2 and patient 1 were
differentiated for 4 days into myotubes, treated with AONs as
described above, and cells were then harvested with ice-cold RIPA
buffer (150 mM NaCl, 0.1% SDS, 50 mM Tris, pH 7.4, 2 mM
EDTA, and 1% Triton X-100) supplemented with Protease Inhibitor
Cocktail cOmplete, with EDTA (Roche). Total protein concentrations
and GAA activities were measured as described above. For immuno-
blot analysis, 10 mg of total protein was heat denaturated for 5 min at
www.moleculartherapy.org95C with sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 25%
glycerol, 0.01% bromophenol blue, and 5% b-mercaptoethanol) and
loaded on a Criterion TGX 4%–15% gel (Bio-Rad). Proteins were
transferred onto 0.45 mm nitrocellulose blotting membranes (GE
Healthcare). The membranes were blocked for 1 hr in Odyssey block-
ing buffer (LI-COR Biosciences) (4 diluted in PBS) and stained for
1 hr with rabbit-a-GAA (Abcam 137068 1:1,000) and mouse-
a-GAPDH (Millipore MAB374 1:1,000) for 1 hr in Li-Cor blocking
buffer. The blot was washed for three times with PBS-T (0.1% Tween,
Sigma-Aldrich), incubated for 30 min with IRDye 700/800 secondary
antibodies (LI-COR Biosciences) in PBS-T, and washed three times
with PBS-T. Immunoblots were scanned with the Odyssey Infrared
Imaging system (LI-COR Biosciences). Bands were quantiﬁed with
Odyssey software (LI-COR Biosciences). Standard curves were gener-
ated for each antibody (GAA and GAPDH) using 2-fold dilution
series. The formulas generated from the linear range were used to
quantify the active form of GAA (76 kD) and GAPDH. Values
were corrected for background, which was obtained from an empty
position on the blot.
Statistical Analysis
All data represent mean ± SD, and p values refer to two-sided t tests.
Bonferroni multiple testing correction was applied where necessary.
A p value < 0.05 was considered to be signiﬁcant. Data showed normal
variance. There was no power calculation in any of the experiments.
No randomization method was used. No samples were excluded from
the analyses. Experiments on expansion of iPS-derived muscle pro-
genitors, differentiation into myotubes, and AON treatment have
been performed at least two times. Investigators were not blinded
to the identity of the samples.
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